Theravance Biopharma, Inc.

TBPH · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$3,615$54,835-$13,579-$15,527
Dep. & Amort.$1,407$927$1,052$695
Deferred Tax$994-$10,691-$1,852-$6,589
Stock-Based Comp.$0$4,543$4,877$5,826
Change in WC-$16,880$157,796$51,937$13,887
Other Non-Cash$4,356$664$604$806
Operating Cash Flow-$6,508$208,074$43,039-$902
Investing Activities
PP&E Inv.$0-$34$0-$190
Net Acquisitions$0$0$0$0
Inv. Purchases-$124,746-$56,574-$1,968-$40,013
Inv. Sales/Matur.$24,500$20,350$32,600$55,889
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$100,246-$36,258$30,632$15,686
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$278$0$20$30
Stock Repurch.-$678-$503-$874-$528
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$133
Financing Cash Flow-$400-$503-$854-$365
Forex Effect$0$0$0$0
Net Chg. in Cash-$107,154$171,313$72,817$14,419
Supplemental Information
Beg. Cash$281,927$111,450$38,633$24,214
End Cash$174,773$282,763$111,450$38,633
Free Cash Flow-$6,508$208,040$43,039-$1,092